L & S Advisors Inc Lowers Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

L & S Advisors Inc reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 22,023 shares of the medical equipment provider’s stock after selling 404 shares during the quarter. Intuitive Surgical accounts for 1.3% of L & S Advisors Inc’s investment portfolio, making the stock its 12th largest position. L & S Advisors Inc’s holdings in Intuitive Surgical were worth $11,495,000 as of its most recent filing with the SEC.

Other hedge funds have also recently made changes to their positions in the company. Atala Financial Inc acquired a new position in shares of Intuitive Surgical in the fourth quarter valued at approximately $25,000. Berbice Capital Management LLC purchased a new position in Intuitive Surgical in the fourth quarter worth approximately $26,000. BankPlus Trust Department purchased a new stake in shares of Intuitive Surgical in the 4th quarter valued at approximately $28,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter valued at $31,000. Finally, Decker Retirement Planning Inc. purchased a new stake in shares of Intuitive Surgical during the 4th quarter worth $36,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of ISRG opened at $491.84 on Friday. Intuitive Surgical, Inc. has a 1-year low of $364.17 and a 1-year high of $616.00. The stock has a market cap of $175.18 billion, a price-to-earnings ratio of 76.73, a price-to-earnings-growth ratio of 5.85 and a beta of 1.43. The firm has a 50 day simple moving average of $556.28 and a 200-day simple moving average of $532.34.

Insider Activity

In related news, Director Amal M. Johnson sold 4,635 shares of the company’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the transaction, the director now directly owns 12,275 shares in the company, valued at approximately $6,955,015. This represents a 27.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Jamie Samath sold 94 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $571.11, for a total value of $53,684.34. Following the completion of the transaction, the chief financial officer now directly owns 2,630 shares in the company, valued at $1,502,019.30. This trade represents a 3.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,754 shares of company stock worth $17,691,621 over the last three months. 0.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ISRG shares. Robert W. Baird cut their price target on Intuitive Surgical from $707.00 to $600.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 18th. Raymond James raised their price target on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a research note on Friday, January 24th. Jefferies Financial Group boosted their price objective on Intuitive Surgical from $475.00 to $575.00 in a research note on Monday, January 27th. Piper Sandler reiterated an “overweight” rating and set a $670.00 price target (up previously from $538.00) on shares of Intuitive Surgical in a research note on Friday, January 24th. Finally, Barclays increased their target price on shares of Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus price target of $611.86.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.